Xin Jing Bao·2026-01-02 06:03Core Viewpoint - The total amount of intellectual property licensing for Chinese innovative drugs to international multinational corporations (MNCs) reached $60 billion in the first half of the year, surpassing the total for the entire year of 2024, indicating a strong growth in the sector and its ability to support innovation despite previous market weaknesses [1]. Group 1: Industry Insights - The capital obtained from licensing agreements for Chinese innovative drugs has exceeded the financing from IPOs in recent years, highlighting the importance of these agreements for the development of innovative pharmaceuticals in China [1]. - Chinese innovative drugs have become a significant representation of global innovation, showcasing the country's advancements in the pharmaceutical industry [1].